---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-121296"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2025-05-16T23:59:59+00:00"
generated_at: "2026-05-21T02:45:09.489388+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioMarin acquires Inozyme for $4.00/share (~$270M cash); adds late-stage ENPP1 therapy

## Summary
- All-cash tender offer at $4.00 per share; total equity value ~$270M; expected to close Q3 2025.
- INOZYME's lead asset INZ-701 is a Phase 3 enzyme replacement for ENPP1 Deficiency; first pivotal data in children expected early 2026.
- Inozyme Board unanimously recommends; stockholders representing ~11.2% of shares have entered support agreements.
- BioMarin reaffirms FY2025 guidance and plan to achieve 40% Non-GAAP Operating Margin in 2026.
- Transaction not subject to financing condition; Goldman Sachs advised BioMarin, Centerview advised Inozyme.

## SEC filing metadata
- accession: 0001193125-25-121296
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2025-05-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000119312525121296/0001193125-25-121296-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000119312525121296/d833625d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-121296
- JSON: https://secwatch.observer/filing/0001193125-25-121296.json
- Plain text: https://secwatch.observer/filing/0001193125-25-121296.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.